RxDoctor Payments DataLook up a doctor →

Alex Makalinao, MD

Hematology & Oncology · Las Vegas, NVNPI 1598790602

Payments from drug & device makers

$30,993in general payments, 2019–2025

Across 630 payments — averaging $49.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$11K
  • Exelixis Inc.$4K
  • Ipsen Biopharmaceuticals, Inc$2K
  • Pfizer$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Johnson & Johnson$734
  • plus $9K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)61$11,351
Exelixis Inc.15$4,319
Ipsen Biopharmaceuticals, Inc8$2,427
Pfizer47$1,672
E.r. Squibb & Sons, L.L.C.66$1,123
Johnson & Johnson24$734
Novartis36$652
Amgen27$570
Bayer22$524
Sanofi24$521
Seagen Inc.17$496
Genentech USA, Inc.21$488
Pharmacyclics LLC, An Abbvie Company19$480
Astellas Pharma US Inc20$472
Bristol Myers Squibb20$461
Incyte Corporation21$416
Lilly USA, LLC17$352
Eisai Inc.16$335
Merck16$313
Blueprint Medicines Corporation7$275
Daiichi Sankyo Inc.10$242
Karyopharm Therapeutics Inc.15$238
Regeneron Healthcare Solutions, Inc.7$184
Stemline Therapeutics Inc.1$172
Gilead(2 entities)6$144
EMD Serono, Inc.7$130
Jazz Pharmaceuticals Inc.6$128
Sanofi-aventis U.S. LLC2$124
Janssen Scientific Affairs, LLC1$102
AVEO Pharmaceuticals, Inc.1$100
AbbVie4$95
Takeda Pharmaceuticals U.S.A., Inc.3$88
Lexicon Pharmaceuticals, Inc.4$84
Tesaro, Inc.3$80
Taiho Oncology, Inc.3$76
Verastem, Inc.4$71
Helsinn Therapeutics (U.S.), Inc.4$64
AMAG Pharmaceuticals, Inc.3$62
Boehringer Ingelheim3$59
Epizyme, Inc.2$53
Agios Pharmaceuticals, Inc.2$47
Tersera Therapeutics LLC2$45
GSK2$44
Puma Biotechnology, Inc.2$40
Global Blood Therapeutics, Inc.2$37
EUSA Pharma (US) LLC2$35
Foundation Medicine, Inc.2$34
Sobi, Inc1$33
Advanced Accelerator Applications2$30
Otsuka America Pharmaceutical, Inc.1$30
Chiesi USA, Inc.2$29
Array Biopharma Inc2$28
Aurobindo Pharma USA, Inc.1$25
Dova Pharmaceuticals1$24
Myovant Sciences Inc.1$24
Apo-pharma USA, Inc.1$21
CTI Biopharma Corp.1$21
Morphosys, US Inc.1$21
Spectrum Pharmaceuticals Inc.1$21
Dendreon Pharmaceuticals LLC1$19

How this compares

$30,993 in reported general payments places this provider in the 45th percentile of 82 hematology & oncology providers in Nevada.

See all hematology & oncology providers in Nevada →

Medicare billing

Part B allowed, 2024
$913,380
Medicare patients
201
Services billed
35,980

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Las Vegas

See the full list for Nevada →

Where these figures come from

Is this you, or does something look wrong? →